Shilling P D, Richelson E, Feifel D
Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093, USA.
Behav Brain Res. 2003 Jul 14;143(1):7-14. doi: 10.1016/s0166-4328(03)00037-8.
Centrally administered neurotensin (NT) produces behavioral and biochemical effects that are very similar to the effects of antipsychotic drugs. Therefore, there is much interest in the potential use of NT agonists as antipsychotic drugs. We have previously reported that PD149163, a NT(8-13) analogue, produced effects on prepulse inhibition (PPI) of startle after systemic administration that were suggestive of an atypical antipsychotic-like drug profile. To determine if these effects are shared by other peripherally administered NT agonists, we tested the effects of NT69L, a recently developed NT agonist that penetrates the CNS, on drug-induced PPI deficits. In the first experiment, rats received subcutaneous (s.c.) injections of NT69L (vehicle, 0.08, 0.25, and 1.0mg/kg) followed 30min later by subcutaneous saline or D-amphetamine (2.0mg/kg). In the second experiment, NT69L injections were followed by saline or the non-competitive NMDA antagonist dizocilpine (0.1mg/kg). Both D-amphetamine and dizocilpine significantly decreased PPI as expected. In the first experiment, NT69L significantly increased PPI levels at baseline and after D-amphetamine. In the second experiment, NT69L attenuated PPI deficits produced by dizocilpine, without increasing baseline PPI. In addition, NT69L had no effect on startle magnitude. The effects of NT69L in these studies were similar in some ways to the effects of PD149163 and were also consistent with the preclinical effects of atypical antipsychotic drugs. These data provide further support for the notion that NT agonists may have use as novel antipsychotic drugs. Furthermore, the ability of NT69L and PD149163 to attenuate dizocilpine-disrupted PPI, an antipsychotic drug effect not mediated by dopamine, suggests that NT agonists may produce some of their antipsychotic-like effects by modulating neurotransmitter systems other than dopamine, such as serotonin, noradrenaline or glutamate.
中枢给予神经降压素(NT)会产生行为和生化效应,这些效应与抗精神病药物的效应非常相似。因此,人们对NT激动剂作为抗精神病药物的潜在用途非常感兴趣。我们之前报道过,NT(8 - 13)类似物PD149163在全身给药后对惊吓前脉冲抑制(PPI)产生的效应提示其具有非典型抗精神病药物样的特性。为了确定其他外周给予的NT激动剂是否也有这些效应,我们测试了最近开发的能穿透中枢神经系统的NT激动剂NT69L对药物诱导的PPI缺陷的影响。在第一个实验中,大鼠皮下注射NT69L(溶剂、0.08、0.25和1.0mg/kg),30分钟后皮下注射生理盐水或D - 苯丙胺(2.0mg/kg)。在第二个实验中,NT69L注射后给予生理盐水或非竞争性NMDA拮抗剂地佐环平(0.1mg/kg)。正如预期的那样,D - 苯丙胺和地佐环平均显著降低了PPI。在第一个实验中,NT69L在基线和D - 苯丙胺给药后显著提高了PPI水平。在第二个实验中,NT69L减轻了地佐环平产生的PPI缺陷,而没有提高基线PPI。此外,NT69L对惊吓幅度没有影响。NT69L在这些研究中的效应在某些方面与PD149163的效应相似,也与非典型抗精神病药物的临床前效应一致。这些数据进一步支持了NT激动剂可能用作新型抗精神病药物的观点。此外,NT69L和PD149163减轻地佐环平干扰的PPI的能力,这是一种不由多巴胺介导的抗精神病药物效应,表明NT激动剂可能通过调节多巴胺以外的神经递质系统,如5 - 羟色胺、去甲肾上腺素或谷氨酸,产生一些类似抗精神病药物的效应。